CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y Posted byZacks Equity Research February 16, 2022 Leave a comment on CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.